TuHURA posts $15.7M net loss through Q3 2024; convertible debt rises to $24.4M

TuHURA Biosciences, Inc./NV

Net loss of $15.7M for nine months ended Sep 30, 2024 vs $26.6M prior year (prior year included $16.2M IPR&D charge).
Operating loss of $12.0M vs $27.1M YoY; R&D spend up to $9.4M from $7.5M.
Cash position $19.6M at Sep 30, 2024, up from $3.7M year-end 2023 after $28.6M convertible note issuance.
Convertible notes payable net of discount total $24.4M; derivative liability of $2.9M recorded.
Stockholders' deficit worsened to $(2.8M) from $(1.6M); closed merger with Kintara on Oct 18, 2024.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.